---
document_datetime: 2026-02-24 14:10:38
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/fymskina-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: fymskina-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.552658
conversion_datetime: 2026-02-25 11:32:26.616646
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Fymskina

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C. Safety, efficacy, pharmacovigilance | 23/02/2026                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000324634                        | changes - C.z Other variation - Accepted C.z - to update sections 3 and 6.6 of the SmPC and corresponding section 6 and 'instruction for administration' of the PL to correct minor inconsistencies in the visual description of the Fymskina pre-filled syringe solution and ensure consistent wording across all relevant sections.   |            |                 |                                                                                                   |
|------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|---------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000308904    | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                   | 18/11/2025 |                 |                                                                                                   |
| Variation type IA_IN / EMA/VR/0000284868 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                     | 10/07/2025 | Annex II and PL |                                                                                                   |
| Variation type IA / EMA/VR/0000285202    | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted                                                                                                            | 08/07/2025 |                 |                                                                                                   |
| Variation type IB / EMA/VR/0000266712    | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet                                                                                                                                                                                                                                                 | 19/05/2025 | SmPC and PL     | To update section 4.5, 4.8 and 5.2 of the SmPC, to add drug-drug interaction information based on |

<div style=\"page-break-after: always\"></div>

| of a generic/hybrid/biosimilar products change Implementation new additional submitted   |
|------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000248050   | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted   | 03/03/2025   | SmPC   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|